Scholorship focused on Instrumentation, Analytical Chemistry and Environmental Science.

The Department of Physical Sciences at the Munster Technological University (MTU) has announced the O'Regan Scholarships to support students registered on programmes focussed on Instrumentation, Analytical Chemistry and Environmental Science. 

In recognition of one of its former graduates, Honorary Fellow Mr Brendan O’Regan, Physical Sciences is now offering scholarships to students registered in their first year in September 2022 on a range of courses delivered by the department in 2022.

The scholorship is named for industry leader  Brendan O'Regan*. He is a pioneer in the field of Automation best known for his work in founding Zenith Technologies, the Cork-based global leader in Smart Factory Solutions for advanced manufacturing sectors such as BioPharma. A graduate of the university he is also an honorary fellow.

Brendan O'Regan

The 2022 O’Regan Scholarships is for prospective students of programmes in the Department of Physical Sciences. Physical Sciences offers full time CAO entry and part time undergraduate courses in core areas of Instrumentation/Industrial Physics, Analytical Chemistry and Environmental Monitoring Science and has a long-standing tradition of educating highly skilled graduates to support the region’s advanced manufacturing sectors. The department is also strongly involved in the training of post graduate research students to MSc and PhD level in areas such as photonics and analytical science. Further details of the department can found at physicalsciences.cit.ie.

Applications are open to students who have applied through the CAO to study on the following programmes:

• BSc (Honours) Instrument Engineering MT883
• BSc Applied Physics & Instrumentation MT782
• BSc (Honours) Industrial Physics CK409
• BSc (Honours) Environmental Science and sustainable Technology MT878
• BSc (Honours) Analytical Chemistry with Quality Assurance MT874
• BSc Analytical and Pharmaceutical Chemistry MT774

The value of the scholarship will be €1000/year for 4 years for the level-8 programmes and €1000/year for 3 years for the level-7, with an additional €1000 for students that progress directly from the level-7 to the level-8 programme.

The awarding of the O'Regan scholarships will be based on a Personal Statement and ranking of Leaving Certificate results for students registered on the programme in September 2022. Applications will be made directly to the head of department, Dr Donagh O'Mahony in September 2022.

---

* A profile of Brendan O'Regan and his work (YouTube)

@MTU_ie @ZT_Global #PAuto #Environment #Ireland

Software partnership strengthens data analysis.

In recent years, the Life Science industry has started to realize the benefits of Multivariate Data Analysis (MVDA). Multivariate technology solutions continue to deliver tangible business outcomes and have become very relevant for all Life Sciences companies. It’s in this context that Zenith Technologies, (a Cognizant Company*), has announced a partnership with Sartorius Data Analytic, formerly Umetrics, the data analytics division of leading biotech company Sartorius. The agreement will see Zenith become a solution delivery and training partner to Sartorius Data Analytics for the Umetrics® Suite products.

“Partnering with Zenith Technologies will help us grow and better service our global customers with local needs. Sartorius provides researchers with tools to obtain critical process insights faster and with modeling technologies to manufacture biologics more efficiently, it is a perfect complement to our existing services,” says Mark Demesmaeker, Head of Data Analytics for Sartorius.

Sartorius Data Analytics are leaders in multivariate technology providing software for design of experiments (DOE), MVDA and dashboards. They deliver a range of innovative data analytics solutions that are widely used across Life Sciences to aid the production of biopharmaceuticals. This partnership enables Zenith to act as a certified implementation and installation partner for the complete Umetrics® Suite which includes, MODDE®, SIMCA® and SIMCA®-online.

SIMCA®-online is a real-time prediction software that provides a complete set of interactive and visual monitoring tools to ensure that batch and continuous operation run smoothly. SIMCA®-online can also be used to estimate or predict parameters which cannot be directly measured, using correlations of all other measured values in the process. A critical enabling component for successful implementation of SIMCA®-online, is access to high quality data.

Bringing together Zenith’s expertise in implementation of Historian and the Distributed Control Systems (DCS) in the Pharmaceutical sector, the partnership will enable enhanced support for clients in the Pharmaceutical sector.

Jacqueline Hora, Data Analytics Consultant and Sartorius Account Partner from Zenith Technologies, A Cognizant Company said: “We are delighted to enhance our data analytics offering through this new partnership with Sartorius. Our closer involvement with Sartorius ensures we can build data into the manufacturing system lifecycle from the very beginning, which will provide customers with access to contextualized, deep data that offers a clearer picture from the outset. This collaboration is a natural fit for Zenith and ensures that all of our customers receive comprehensive service and can truly unlock the value of their data.”

“By having the right partners to complement our offering – it will help us focus on the software development and adding new advanced methods to our user-friendly software suite. Zenith has been very easy to work with and the certification as a Partner will ensure that our joint customers can benefit from the right service and support - now and in the future. Going forward, Simplifying Progress will be our key focus and this partnership strengthens that”, says Johan Hultman, Embedded Solutions (OEM) and Partner Manager at Sartorius.

The partnership will provide a range of services to clients in the Pharmaceutical sector including installations, data connector configuration, multivariate model building, customized training solutions and SIMCA®-online configurations. These services will be delivered by Sartorius certified personnel and will be incorporated into Zenith’s current site services packages.

David Staunton, Global Director Services from Zenith Technologies, A Cognizant Company, summarizes the value created by the partnership, “As the global partner with Sartorius, we are uniquely positioned to help our customers realize the benefits of the Umetrics® Suite and improve their business outcomes”.

* Life sciences technology leader acquired (20/6/2019)

@ZT_Global @Umetrics_Suite #PAuto #Biotech #Pharma

Life sciences technology leader acquired.

Zenith Technologies, the life sciences manufacturing technology services company headquartered in Cork (IRL) is to be acquired by Cognizant. Their more than 800 people will become part of Cognizant’s Life Sciences business unit.

Joe Haugh
Zenith's CEO

“In joining Cognizant, we are bringing together two respected life sciences service provider brands with complementary technology and manufacturing operations expertise,” said Joe Haugh, Chief Executive Officer, Zenith Technologies. “It’s an exciting time for us, with the life sciences industry embracing digital transformation to enable more flexible and efficient manufacturing facilities to bring new treatments to market faster. Our combined business will drive process excellence through tighter integration of manufacturing processes and systems, the efficient harnessing of information and analytics across the manufacturing value chain, and the adoption of IoT technologies delivering manufacturing 4.0. Together, we are well-positioned to help clients more efficiently produce the life-changing medicines and medical devices for patients who need them most.”

The acquisition extends Cognizant’s capabilities for designing, implementing and managing end-to-end operational and information technology systems for connected biopharmaceutical and medical device manufacturers. Interconnected “smart factories” have become a strategic priority for the industry, with production systems and processes becoming more complex because of research advances and increased demand for large-molecule biologics.

Brendan O'Regan, 
Zenith's Founder

The combined Cognizant-Zenith Technologies expertise will deliver a range of Industry 4.0 capabilities, from factory design consultation, machine sensor and controller instrumentation, supervisory control, and data acquisition, to manufacturing execution systems, batch automation, enterprise resource planning integration and managed services. The company’s operating hubs in Ireland, Germany, India, Singapore, the United States and other sites around the world are located near manufacturing facilities of many Cognizant clients. Cognizant is a leading services provider to the life sciences industry, working with all of the world’s top 30 life sciences companies.

“Industry 4.0 solutions, encompassing Internet of Things (IoT), automation and analytics, are a strategic focus area for Cognizant,” said Brian Humphries, Chief Executive Officer, Cognizant. “In acquiring Zenith Technologies, we expand Cognizant’s IoT portfolio and extend our life sciences domain expertise by becoming a single-source provider of end-to-end smart factory capabilities. Together, we are better positioned to help clients realize information and operational technology convergence in their manufacturing operations, and advance the development of life-saving drugs, biologics, specialized pharmaceuticals and medical devices. We look forward to welcoming Zenith Technologies’ employees to Cognizant.”

The transaction is expected to close in the third quarter of 2019, subject to satisfaction of closing conditions, including regulatory review. Financial details were not disclosed.

Founded in 1998, Zenith Technologies operates on five continents, with 16 locations around the globe. Zenith Technologies works with nine of the world’s 10 largest biopharmaceutical manufacturers, implementing and supporting their manufacturing lifecycle software through its Consultancy, Manufacturing Digital and Automation Systems Integration, and Manufacturing Site Services business lines.

A recognized industry leader, Zenith Technologies was named “Pharma Supplier of the Year” at the 2018 Pharma Industry Awards, which acknowledge companies demonstrating innovation and excellence in the Irish biopharma industry.

The Zenith story to date!

@ZT_Global @Cognizant #PAuto #Pharma #Ireland @CognizantNews

Phenomenal growth in China for systems house.

Zenith Technologies has reported 400 per cent growth in its Chinese operations in the last 3 years.
The company now has a presence working on sites across five Chinese cities – Shanghai, Suzhou, Xi’an, Hangzhou & Guangzhou - and employs a growing team to work across its client base supporting pharma and biotech companies with the implementation of technologies to improve manufacturing efficiencies such as Automation, IT, Manufacturing Execution Systems (MES) and Digital and Data Analysis.

Liang Zhou, China Manager with 
Trevor Marshall, Global Engineering Director.

With the Chinese life sciences market currently set as the world’s second largest national market, and with an expected value of $220 billion by 2022, Zenith plans to double its operations in the country over the next three years and expand its work with local companies as well as continuing to support global multinationals.

Liang Zhou, General Manager of Greater China said: “The Chinese market has been leading the way in revolutionary cell therapy innovations, which are changing the face of medicine delivery. There is growing interest in the adoption of automating processes in this area as companies build a new generation of facilities in line with stringent international standards with a view to supplying across the world.

“We are well placed to support clients here who would like to adopt these solutions and have already played an integral role in the development of technologies to oversee these key cell therapy innovations.”

Zenith’s success in China represents the company’s latest endeavour in the Asian market having first set up a presence on the continent in 2002 with the opening of its regional headquarters in Singapore.
In 2008 the company set up an office in India, which now hosts more than 100 employees and serves as a global support hub to deliver software projects anywhere in the world, featuring a remote engineering centre and 24/7 IT support desk service.

Zenith, founded in Ireland in 1998, has 16 offices worldwide with over 900 skilled employees delivering manufacturing software to the life sciences industry. Across Asia the company now has a total workforce of more than 200 professionals and is actively looking to new Asian markets to expand its footprint to support the burgeoning number of life science hubs.

Bryan McSwiney, Asia Director said: “After more than 15 years in the Asian market, a quarter of our global operations are now based here and the latest growth figures from China demonstrate that we go from strength to strength.

“We now have an established presence in five Chinese cities – a significant footprint within a relatively short space of time – as well as a thriving support hub in India and a widely recognised HQ in Singapore.

“With a solid foundation now firmly established in the Asian market, we look forward to building on our successes and working closely with local and multinational companies on the continent who can benefit from the diverse range of technologies we can introduce into manufacturing facilities.”

 @ZT_Global  #LifeScience #PAuto #Systems #China

Digital future increases consultancy demand.

Zenith Technologies has seen a 150% rise in demand for its consultancy arm services. Their Consultancy team offers guidance and support to businesses with the implementation of new digital technologies and has seen an increasing appetite for digitised manufacturing and using data to improve GMP manufacturing over the past 12 months

The growth of the service in 2018 was driven by a need to aid customers in collecting, contextualising and finding insights in their stored data. These insights can then be used to make informed decisions on production processes and the supply chain.

Jaqueline Hora, Global Digital and Data Analytics Lead at Zenith Technologies said: “The life science industry has seen a remarkable trend towards innovation utilising data and technology effectively. Digital strategies as well as manufacturing execution systems (MES) and automation are in great demand as a result.
“For customers implementing these digital strategies, project decision support as well as process, technology and project execution knowledge, are essential to ensure success.
“Our Consultancy team supports customers that are considering new technology projects and assists in developing strategies, governance and standards to provide a framework for success.
“Whether it be justifying ROI, validating a customer’s strategy, process and methodology implementation expertise or help with technology selection, Zenith has been there to support its customer base.
“Zenith’s intimate understanding of manufacturing systems, extensive process knowledge and significant experience serving the life science sector has ensured that our customers have the insight needed to make the best decision.”

The increase is in part a direct result of the emergence of Industry 4.0 with data integrity, data analytics, the internet of things, and cloud strategies becoming a reality throughout the life science industry.

The team’s growth is projected to continue into 2019 as the life science industry increases its focus on digitisation and using data to improve GMP manufacturing practices.

In a recent survey of the industry, Zenith found nearly 60% of participants believe that Industry 4.0 will drive the most change in life science over the next 5 years, with 75% of those aiming to invest in people to take advantage of emerging technologies.

 @ZT_Global #PAuto #LifeSciences

Digital manufacturing in the life sciences industry.

Zenith Technologies recently conducted an industry survey that suggests the digitalisation of manufacturing is a top priority.

The company conducted a survey of business and operational leaders across the life science sector on the trends and technologies that may revolutionise the industry over the coming years.

The research suggested an increasing appetite for Industry 4.0 – which focuses on using data and information to revolutionise GMP manufacturing.

Nearly 60% of those surveyed believe that Industry 4.0 will drive the most change in life science over the next 5 years, with 75% of those aiming to invest in people to take advantage of emerging technologies.

It also uncovered the main motivators for technology investment were cost and time saving, with more than 70 % of respondents citing these reasons.

Following on from these findings, Zenith published a whitepaper ‘Industry 4.0: Revolutionising life science manufacturing through connected systems and data’ written by global services director, David Staunton and MES project manager, Ryan McInerney.

The paper examines technological advances that are driving the next phase of pharmaceutical manufacturing, improving quality and reducing waste.

David Staunton said: “The life science industry has used data and information to drive improvements in GMP Manufacturing for decades and there is now an opportunity to take it to the next level.”
“The foundation of life science GMP manufacturing is to know your process and industry 4.0 allows us to stay true to who we are, while at the same time revolutionising GMP manufacturing.”

@ZT_Global  #PAuto @ramarketingpr

Research reveals barrier to serialisation compliance.

According to new industry research more than half (54%) of industry professionals believe that the cost of implementing serialization is the greatest hurdle to compliance.

The research, conducted by serialization software provider, SEA Vision and  Zenith Technologies, highlighted that the substantial investment required to implement a serialization solution is cause for concern ahead of regulatory deadlines in the US and Europe.

A further 33% of survey respondents stated the implementation process would be a drain on internal resource. Others (31%) cited tight timescales as a pain point, a statistic that is further supported by the announcement that the FDA will delay the active enforcement of the Drug Supply Chain and Security Act (DSCSA) due to a lack of readiness across the industry.

Commenting on the research, Carlos Machado, serialization director at SEA Vision US said: “The new regulations in the EU and the US represent a substantial upfront investment for companies across the supply chain and many smaller players are struggling to implement a suitable process as a result.

“The resource required in terms of cost and manpower is a notable barrier to compliance, but added to that, the time it takes to develop a solution has been gravely underestimated by a large part of the industry. Many (37%) of our survey respondents expressed concerns surrounding the potential disruption to product supply as a result of technical issues and downtime, which clearly demonstrates the impact serialization could have at an operational level.

Consolidation across the outsourcing space has been prevalent for some time now and serialization is undoubtedly driving smaller companies to consider partnerships to offset a lack of manpower and budget. However, 36% also believed that there was a knowledge gap in their existing teams surrounding serialization, making external expertise vital to ensuring compliance."

Machado continued: “With time and cost becoming a growing concern across the pharmaceutical industry, it’s no surprise that smaller partners, particularly contract manufacturers, are looking to consolidate to expand their internal resource.

“In addition to consolidation and a growing trend to outsource serialization requirements, it is also likely that we will see an increased reliance on third party implementation specialists with the knowledge and expertise to effectively introduce the necessary changes and also help companies realise the wider business benefits that can be achieved. For example, implementing serialization can also help to improve line performance and overall equipment effectiveness (OEE).”

In 2016, SEA Vision and Zenith Technologies formed a global partnership to support pharmaceutical companies with the impending challenge of installing and integrating serialization across drug manufacturing sites.

The collaboration brings together Italian-based SEA Vision’s serialization system along with global Zenith Technologies’ ability to integrate systems and deliver ongoing technical support at a local level.

 @ZT_Global  #PAuto #Pharma  @ramarketingpr

Dangerous underestimation of urgency in meeting drug regulations.

New industry research reveals that more than one third (36 per cent) of pharmaceutical manufacturers and contract packagers are not currently preparing for global serialization requirements, despite impending deadlines.

The research, conducted by serialization system provider SEA Vision and life science technology firm Zenith Technologies, highlights an urgent need for companies to turn their attention to meeting the demands of the US Drug Supply Chain Security Act (DSCSA) and the European Falsified Medicines Directive (FMD).

Out of those companies that are not preparing for the new regulations, around half (51 per cent) say it is because they don’t currently have enough internal resource to devote to serialization, while 15 per cent believe it is too early to begin preparations.

Commenting on the research, Carlos Machado, serialization director at SEA Vision US, said: “Our research has confirmed that many companies are under-estimating the enormity of the task at hand. Preparing for serialization is a complex process that is so much more than simply integrating new technology on a packaging line. Instead, it should be a company-wide initiative, involving all corners of an organisation and the wider pharmaceutical supply chain.

“Those companies that delay their preparations risk production downtime and loss of business in key markets.”

For 56 per cent of those that have begun their serialization journey, compliance is the only goal of their serialization project at this stage. Just 44 per cent intend to use the process to achieve wider business benefits.

Carlos continued: “While serialization presents a number of challenges, it also creates an opportunity to review business processes and improve productivity. Those companies that embrace the changes and make preparing for the DSCSA and the FMD a priority, have a real opportunity to differentiate their offering, and it is our goal to support this process.”

In 2016, SEA Vision and Zenith Technologies formed a global partnership to support pharmaceutical companies with the impending challenge of installing and integrating serialization across drug manufacturing sites.

The collaboration brings together Italian-based SEA Vision’s serialization system along with global Zenith Technologies’ ability to integrate systems and deliver ongoing technical support at a local level.

@SEA_Vision  @ZenithIre  #PAuto #Pharma

Phenomenal growth in MES sales!

A global life science technology firm has surpassed the €20 million milestone for sales of its manufacturing execution system (MES) services.

Zenith Technologies, which is headquartered in Ireland,  provides MES and data historian deployment and support services to pharmaceutical and medical device manufacturers globally. The company has seen sales for this part of the business grow significantly over the last five years, with an average of over 35% year on year growth.

Commenting on the growth trend, James O’Brien (right), global MES business unit lead at Zenith Technologies, said: “MES has been the fastest growing segment of our offering and now represents almost a third of our business. Factors such as a greater regulatory focus on data integrity and customer demand for improved production performance have led to growing use of MES solutions within the pharmaceutical, biotech and medical device industries, which have traditionally been slow to adopt new technologies.

“The UK in particular is quickly becoming an MES centre of excellence, with MES sales representing 70% of our business in this market. Similarly, the US & Asia markets offer huge growth potential as the adoption of MES within the life science industry continues to grow across the globe.”

Zenith Technologies now works with nine of the top ten pharmaceutical companies globally and during 2016 its team of engineers grew by almost 40% to over 700 employees.

To strengthen its ability to support customers in Europe, the US and Asia and accelerate further growth, the company has recently formed a number of strategic partnerships with MES technology providers, including Werum IT Solutions , AspenTech and LZ Lifescience. This will enable Zenith to support customers worldwide with on-site implementations of MES solutions designed to improve productivity, meet regulatory requirements during life science manufacturing and ultimately deliver vital medicines to patients as efficiently as possible.

@ZenithIre #PAuto @ramarketingpr #MES

Serialisation research survey!

"What is the biggest challenge you face when preparing for pharmaceutical serialisation? Are you clear what the global requirements for serialization are?" asks Zenith Technologies.

Zenith along with with SEA Vision is conducting some serialisation research to better understand users' views.

Participants in this short serialisation research survey will gain exclusive access to a free e-book with tips and guidance to prepare for new serialisation regulations, while also helping to significant business improvements.

Participation in serialization research will ensure receiving a summary of the findings (though responses will of course remain anonymous).

 @ZenithIre  #PAuto @SEA_Vision

MES business has new leader!

James O’Brien has been appointed by Zenith Technologies to lead its manufacturing execution system (MES) business to its next phase of growth.

James O'Brien

Over the past five years, Zenith Technologies has strategically grown its MES offering globally to meet growing demand for technology-based manufacturing efficiency programs in the life science sector.

In his role as MES business unit lead, James will use his background in software development, consultancy and technology implementation to continue to develop Zenith Technologies as a world leader in the provision of MES solutions and services to the life science industry.

This company assists pharmaceutical and medical device manufacturers with the implementation of MES solutions, providing on-the-ground support. James will be focused on forming further collaborations in the industry to support life science companies with the transition to MES and automated systems.

Commenting on the appointment, Jim Lehane, director at Zenith Technologies, said: “James has worked with us as a senior MES engineer for a number of years, supporting some of the world’s leading pharmaceutical companies with global automation projects. In his new role as MES business unit lead, James will drive Zenith Technologies forward to further success in the US and Europe, leveraging our global presence, skilled engineers and world-class implementation and support services.”

James’ appointment comes as MES technology is being adopted by the life science industry at a faster rate than any other vertical market.1 To support demand, the firm recently announced a partnership with MES software provider Werum IT Solutions.

Jim continued: “It’s an exciting time for our company, as pharmaceutical and medical device manufacturers are recognising the benefits of MES and adoption is increasing at a steady rate. In particular, we are experiencing increasing demand in the US market, which has led us to open two new offices in Oakland and San Diego.”

Based in Bluebell, PA, James will lead Zenith Technologies’ team of engineers in 16 offices globally to support clients with their manufacturing enterprise solution needs.

He said: “MES technology can dramatically improve productivity during manufacturing, however there are a number of challenges associated with its implementation. It is our goal to assist companies with the transition to MES systems so they can realise the benefits with minimal disruption to their operations.”

 @ZenithIre #PAuto #Pharma #USA #MES

Serialisation director for US project support.

Carlos Machado has been appointed by Zenith Technologies as serialization director to lead the company’s sales, operations, implementation and post project support services in the US.

Carlos Machado

The appointment comes as the pharmaceutical industry faces the challenge of complying with new legal requirements for the authentication and barcoding of licensed drug products from November 2017 in the US and early 2019 in Europe.

Carlos joins Zenith Technologies with significant experience of assisting pharmaceutical manufacturers with track and trace technologies, having worked on more than 75 serialization projects from both an operations and delivery perspective.

In his former role as director of global operations at a leading anti-counterfeiting technology provider, Carlos helped to pioneer the serialization concept and define the future of authentication.

Jim Lehane, director at Zenith Technologies, said: “Serialization is a real challenge for our customers and it’s an important time for us to add further expertise to our team. Carlos’ background in track and trace technologies and his knowledge of the implementation challenges pharmaceutical manufacturers face, make him ideally suited to lead our serialization offering in the US, helping our customers achieve seamless compliance with the new regulations.

“Zenith Technologies has strong partnerships with many of the world’s largest pharmaceutical manufacturers as well as life science companies of all sizes, providing automation consulting and local support services. Carlos’ appointment will help us to take our US offering to the next level.”

Commenting on his appointment, Carlos said: “Serialization is a huge priority for Zenith Technologies as we understand the challenges customers face in addressing supply chain security and preventing the introduction and distribution of counterfeit product into the global marketplace. It is an exciting time to join the firm as we expand our US presence, leveraging our technological experience, sound project management practices, skilled engineers and world-class implementation and support services.

“When it comes to complying with new serialization regulations, the industry, ranging from the top pharmaceutical companies to contract manufacturing organizations (CMOs), understands what needs to be done. The challenge lies in the scale and complexity of the task ahead. In my new position, it is my responsibility to draw on my industry experience and work alongside our customers to simplify the implementation process and provide flawless execution.”

The announcement is the next stage in Zenith Technologies’ goal to assist companies in the US and Europe with the challenge of serialization. The company recently announced a global partnership with software provider SEA Vision to support pharmaceutical companies with the installation and integration of serialization solutions across drug manufacturing sites.

Carlos continued: “Given our combined expertise and remarkable track record, it’s a natural marriage. We will be working exclusively with SEA Vision to improve existing processes and delivery time, implement its technology and systems and enhance the overall customer experience.

“Our organizations are also working towards providing an innovative interactive e-learning environment to assist our customers with serialization training. We are also actively recruiting and adding experienced talent to our serialization taskforce in the US to ensure we can continue to deliver a high level of service at a local level.”

Marco Baietti, commercial director at SEA Vision said: “Carlos provides a unique combination of leadership skills and expertise in the serialization field thanks to his specialist background. We are thrilled to welcome him to the team and look forward to working together to deliver our shared goal to provide the best track & trace solutions and services in the markets that we serve.”

With its US headquarters in Pennsylvania and 14 offices globally, Zenith Technologies is one of the leading companies in delivering full life cycle enterprise, manufacturing and operational support solutions that enable life science businesses to be compliant and competitive.

#PAuto @ZenithIre

Irish automation entrepreneur recognised and honoured.

Zenith's Brendan O’Regan receiving his Cork Institute of Technology STEM Graduate Achievement Award from Dr Guillaume Huyet, Head of Dept of Physical Sciences. Far left, Michael Loftus, Head of Faculty of Engineering & Science. Far right, Dr Hugh McGlynn, Head of School of Science & Informatics.

The professional achievements of Brendan O’Regan, Founder and Executive Chairman of Zenith Technologies, have been recognised by the Faculty of Engineering & Science in CIT. Brendan was amongst the first graduates of CIT’s Instrument Physics programme and also graduated from the Stanford School of Business. He was selected recently to receive the Faculty’s STEM Graduate Achievement Award.

These awards are presented to graduates whose work in science, technology, engineering or mathematics (STEM) has made a significant contribution in a professional and/or societal context.

Michael Loftus, Head of Faculty of Engineering & Science at CIT, said, “Brendan has made a huge contribution to STEM development in the Cork region, leading developments which provide high quality local and international opportunities for STEM graduates. We are delighted to recognise the success that he has achieved on a global scale and wish him well in his future endeavours.”

As a successful entrepreneur and senior executive, Brendan has led the development of a number of technology companies, sourcing and building strong technical and management teams, driving expansion into new territories, and dealing with the cultural and management challenges of global business development. As an experienced technologist, with a proven track record of innovation in process automation and control, Brendan has led a range of organisations to deliver true business benefit to customers by exploiting best-in-class technologies. He has deep domain expertise in life sciences and across all aspects of the supply chain. In addition to his leadership achievements, he has developed deep technical ability in diagnostics, strategic planning, organisation development, team building and strategic exploitation of technology.

As well as his leadership role in Zenith Technologies, Brendan is involved as a stakeholder and executive in a number of allied technology companies.

He is strongly committed to the advancement and promotion of STEM in Ireland. Amongst many other activities, he has been hugely supportive of new programme developments in CIT, providing student project and placement opportunities, as well as creating international employment opportunities for hundreds of local and international STEM graduates.

@CIT_ie @ZenithIre  #PAuto #STEM

Biopharma alliance announced.

Zenith Technologies and GE Healthcare’s Life Sciences business have announced a collaboration to support biopharmaceutical manufacturing deployment.

As part of the partnership, Zenith Technologies’ methodologies, systems and libraries will be offered as a service to GE Healthcare’s clients in bioprocessing. The combined offering is aimed at helping biopharmaceutical manufacturers increase productivity, improve efficiency and reduce costs.

The two companies will integrate process control systems, manufacturing execution system (MES) solutions and other supporting technologies with GE Healthcare’s start-to-finish technologies and solutions for the biopharmaceutical manufacturing industry.

Jan Makela, general manager at BioProcess GE Healthcare said: "The development of our KUBio modular manufacturing facilities and FlexFactory single-use manufacturing platform was fuelled by the need for customers to deploy biopharmaceutical manufacturing capacity more quickly and at a lower cost.

“Implementing these advanced technology platforms requires automation expertise for which we partner with a number of world class companies. With Zenith Technologies’ expertise in automation integration and customer support, we will be able to offer more choice to customers.”

Brendan O’Regan, founder at Zenith Technologies, said: “This is a significant milestone in our development and ushers in a new era of opportunity for both companies.

“GE offers an unprecedented solution to our pharmaceutical customers to help rapidly deploy capacity and significantly reduce time to market. Combined with our manufacturing software systems and on the ground, global support services, we can help biopharmaceutical manufacturers improve their processes and ultimately increase their competitiveness.”

• Headquartered in Cork (IRL) and with 14 offices globally, Zenith Technologies delivers manufacturing software systems that enable life science businesses to be compliant and competitive. The company combines pharmaceutical industry expertise and full life-cycle support, including managed services, with a portfolio of technology application and platform 
experience.

@ZenithIre #PAuto @GE_LifeSciences #PHarma

Global serialization partnership.

Zenith Technologies and SEA Vision have formed a global partnership to support pharmaceutical companies with the impending challenge of installing and integrating serialization across drug manufacturing sites.

Jim Lehane, director of MES & NBI Zenith,  

Marco Baietti,  commercial director, & 

Stefano Cobelli, sales director, SEA Vision 

with Dominic Galvin, chief financial officer, 

Zenith.

The announcement comes after the two companies completed the worldwide implementation of a serialization deployment to aid the production, packaging and supply chain of one of the world’s top 10 pharmaceutical firms.

Initially encompassing the US, Britain, Ireland and Germany, markets where both companies have a strong presence, the collaboration brings together Italian-based SEA Vision’s serialization software along with global Zenith Technologies’ ability to integrate systems and deliver ongoing technical support at a local level.

Jim Lehane, director at Zenith Technologies, said: “We are delighted to have secured the rights to distribute, implement and support SEA Vision’s serialization solution in these key territories.

“The partnership enables pharmaceutical manufacturing and packaging companies to utilise SEA Vision’s products with added on-the-ground assistance from our expert engineers to ensure they can deal with the continuous challenge that serialization brings.

“Given what we’ve already achieved to date in this field and the similarities in our customer base, we are ideally placed to work together with SEA Vision to help clients achieve seamless compliance with the new serialization requirements. We truly believe this is a turn-key solution for installation, integration and support for any company producing licensed products.”

The deal has been unveiled as drug makers begin to seriously turn their attention to the looming legislation changes. The serialization of licensed drug products will be legally required for companies in the EU from 2019 as per the EU Falsified Medicines Directive (EUFMD) Safety Features Delegated Regulation and from November 2017 in accordance with the US Drug Supply Chain Security Act (DSCSA).

Marco Baietti, commercial director at SEA Vision, said: “As a business, we are 100% focused in the pharmaceutical space and are committed to helping companies deal with the challenge of serialization.

“Following the announcement of the timing for the legislation changes, we have experienced a wave of requests from tier two and three pharma companies. This collaboration is therefore designed to give these firms the tools and skills they require to confidently introduce new systems well ahead of the deadlines.

“We are known for our reliability, technical solutions and customer service. Combined with Zenith Technologies’ global reach and proven training expertise, we believe our partnership can benefit pharmaceutical manufacturing companies in all these territories.”

Aside from traditional pharmaceutical companies producing bulk API and finished licensed products, the partnership will also assist contract manufacturing organisations (CMOs) that also need to adapt to the regulations.

Headquartered in Cork and with 14 offices globally, Zenith Technologies is one of the leading companies in delivering manufacturing software systems that enable life science businesses to be compliant and competitive.

SEA Vision, located in Pavia, close to Milan, with subsidiaries in France, Spain and Brazil, was set up in 1995 as a producer of vision systems for the pharmaceutical industry, with the aim to meet control requirements on packaging lines. To date, the company has successfully supplied over 250 complete track and trace systems worldwide.

@ZenithIre #PHarma #Pauto 

Head of Irish Government opens Automation Group's US HQ

During his visit to the US last week,  Mr Enda Kenny TD, Taoiseach, (Head of the Irish Government) officially opened the new US headquarters of Zenith Technologies (Zentek Automation US, Inc.), on Friday last (12th October 2012) in Bluebell, Montgomery County (PEN USA) The Taoiseach was on a trade visit to the United States.

Taoiseach Enda Kenny (left) with
Zenith Founder Brendan O'Regan
at official opening of the US
Headquarters

Zenith Technologies, whose global headquarters are at Ringaskiddy, Cork, is a leading Global Automation and MES Engineering company principally servicing the lifescience industry. Zenith currently employs over 370 people in 14 offices worldwide, with 50 people based in US offices at Pennsylvania, Massachusetts, North Carolina, and California.

Founded in 1998, Zenith expects to double its workforce over the next two years having hired an additional 65 people in Ireland this year alone.

The company provides System Integration, Manufacturing Execution Systems, Managed Services, Consultancy, and ELearning to a large and diverse client base including Amgen, Baxter, BMS, Dow, Grifols, GSK, Merck, Novartis ,Pfizer, and Sanofi.

It was founded in 1998 by Brendan O’Regan and now the company has worldwide revenue of $50M, and US revenues of over $12M. Mr. O’Regan also announced the launch of two new products in the US market on Friday; the Zenith Managed Services Model (ZTMS) and the cloud based Incident Control Room(ICR) offering.

Speaking at the opening, An Taoiseach said:‘I am delighted to officially open Zenith Technologies US Headquarters. Zenith is a leading Irish high-technology company that is achieving strong growth in the US market. Zenith’s success in this highly competitive market is a clear demonstration of how an ambitious company, with an innovative, specialist offering, can compete at the highest levels internationally.
‘It is companies like Zenith that will drive the export growth that will underpin Ireland’s economic prosperity and support valuable Irish jobs. I congratulate Zenith on their operation here in Pennsylvania that will allow them to grow their business in the US market and indeed worldwide’.

The founder and CEO of Zenith , Brendan O’Regan, said: ‘I am delighted to have the Taoiseach of Ireland Enda Kenny TD here today to open our new US headquarters and mark this very significant milestone in our company’s development.

‘I am also very pleased to be announcing the launch of two new products in the US market, the Zenith Managed Services Model (ZTMS) and the cloud based Incident Control Room(ICR) .

‘The Zenith Managed Services (ZTMS) model has been delivering a valuable product in the European region since 2006. This model was developed in response to the Life Science industry requirements to efficiently manage its automation support and optimise the cost of ownership in IT and automation systems. The Managed Services is a new departure for Zenith in the US and is built upon firm experience and successful delivery of value in the European Pharmaceutical Market.

‘The Incident Control Room (ICR) provides independent processes and methods for handling a variety of site incidents encountered during complex processing of pharmaceutical products’, he said.

The Headquarter's opening was attended by a large number of clients and Zenith staff, and US public representatives including Congresswoman Allyson Schwartz and State Representatives Kate Harper and Brendan Boyle.

The company is supported by Enterprise Ireland, the body responsible for the development and growth of Irish enterprises in world markets.

L to R:  Dermot Moynihan, Director, Zenith Technologies, Jim Lehane, Regional Director USA, An Taoiseach Enda Kenny and Brendan O'Regan, CEO, Zenith Technologies and Irish Ambassador to the U.S. Michael Collins